Search
bispecific antibody; bispecific monoclonal antibody
Indications:
- relapsed/refractory multiple myeloma (FDA-approved) (teclistamab, talquetamab)
- precursor B-cell acute lymphoblastic leukemia (blinatumomab)
- treatment of hemophilia A (emicizumab)
Dosage:
- intravenous or subcutaneous administration
- see individual antibody
Adverse effects:
- treatment related adverse effects common (up to 80%)
- neutropenia (40%)
- anemia (28%)
- thrombocytopenia (20%)
- cytokine release syndrome (70%).
Mechanism of action:
- bispecific antibody
- binds antigen on pathological cell & CD3 to redirect T cells to eliminate diseased cells
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
Specific
blinatumomab (Blincyto)
emicizumab-kxwh (Hemlibra, ACE910)
talquetamab
teclistamab-cqyv (Tecvayli)
General
pharmaceutical monoclonal antibody
References
- Topol EJ
Unleashing Our Immune Response to Quash Cancer.
Medscape. Feb 20, 2024
https://www.medscape.com/viewarticle/1000139